AOTI, Inc. (AIM:AOTI)

London · Delayed Price · Currency is GBP · Price in GBX

53.00

-1.00 (-1.85%)

Apr 28, 2026, 4:10 PM GMT

-35.76% (1Y)

Market Cap	57.43M
Revenue (ttm)	49.44M
Net Income (ttm)	1.98M
Shares Out	106.36M
EPS (ttm)	0.01
PE Ratio	36.34
Forward PE	43.20
Dividend	n/a
Ex-Dividend Date	n/a

Volume	33,439
Average Volume	35,776
Open	55.00
Previous Close	54.00
Day's Range	53.00 - 56.00
52-Week Range	25.00 - 99.00
Beta	n/a
RSI	90.22
Earnings Date	Mar 30, 2026

About AOTI, Inc.

AOTI, Inc., together with its subsidiaries, produces, rents, and sells medical devices to resolve severe acute and chronic wounds for customers worldwide. The company offers topical wound oxygen solutions for use in the institutional and the home care settings to improve the health, well-being, and independence of patients; and NEXA, an negative pressure wound therapy system. AOTI, Inc. was incorporated in 2008 and is based in Oceanside, California. [Read more]

Industry Medical - Specialties

Sector Healthcare

Founded 2008

Employees 94

Stock Exchange London Stock Exchange AIM

Ticker Symbol AOTI

Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

AOTI, Inc. Earnings Call Transcript: H2 2025

Revenue grew 14% to $66.5M with strong underlying growth, despite U.S. healthcare headwinds and Arizona payment delays. Awaiting CMS Medicare coverage, which could expand the addressable market 65-fold and drive future growth.

4 weeks ago - Transcripts

AOTI, Inc. Earnings Call Transcript: H1 2025

Revenue grew 21% year-on-year, led by Medicaid and VA segments, despite U.S. regulatory headwinds. High gross margins and strong clinical validation support a positive outlook, with CMS approval expected to be transformational.

7 months ago - Transcripts

AOTI, Inc. Earnings Call Transcript: H2 2024

Revenue grew 33% to $58.4M, driven by Medicaid and commercial expansion, with gross margin rising to 88%. Adjusted EBITDA more than tripled, and the company projects 27–30% revenue growth for 2025, focusing on new state access and value-based care.

1 year ago - Transcripts

AOTI, Inc. Earnings Call Transcript: H1 2024

Revenue grew 26.4% year-over-year, driven by Medicaid and international expansion, with Adjusted EBITDA margin rising to nearly 13%. IPO proceeds strengthened the balance sheet, supporting growth, product launches, and debt reduction. Guidance for >30% revenue growth and 15–20% EBITDA margin is maintained.

1 year ago - Transcripts